{
    "nct_id": "NCT06157892",
    "official_title": "A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors",
    "inclusion_criteria": "General Inclusion Criteria\n\n* Measurable disease according to RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n\nDose Escalation and Optimization Phase Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma or breast carcinoma\n* Locally-advanced, unresectable, or metastatic stage\n* Must have experienced disease progression on or after standard of care therapies or be intolerant of standard of care therapies.\n\nCohort A (HER2-Low Breast Cancer) Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of breast carcinoma\n* Locally-advanced, unresectable, or metastatic stage\n* HER2-low status determined by most recent local assessment (IHC 1+ or IHC 2+/ISH-negative)\n* Prior therapies requirements\n\n  * No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC.\n  * Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated\n  * Have progression on or after, or intolerant to, T-DXd, sacituzumab govitecan, or other topoisomerase I inhibitor therapies, if available as local standard of care therapy\n  * Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy refractory disease:\n\n    * Progressed on â‰¥2 lines of endocrine therapy for LA/mBC AND had received a CDK4/6 inhibitor in the adjuvant or metastatic setting OR\n    * Progressed on 1 line of endocrine therapy for LA/mBC AND had a relapse while on adjuvant endocrine therapy after definitive surgery for primary tumor AND had received a CDK4/6 inhibitor in the adjuvant or advanced setting\n  * Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab with chemotherapy if available as local standard of care therapy.\n  * Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab (or other PD-(L)1 inhibitor) with chemotherapy if available as local standard of care therapy and not medically contraindicated.\n\nCohort B (HER2+ Breast Cancer) Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis breast carcinoma\n* Locally-advanced, unresectable, or metastatic stage\n* HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)\n* Participants must have:\n\n  * Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.\n  * Have progression on or after, or intolerant to, T-DXd or other topoisomerase I inhibitor therapies\n  * No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC\n\nCohort C (HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma) Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma\n* Locally-advanced, unresectable, or metastatic stage\n* HER2-low expression defined as IHC 1+ or IHC 2+/ISH-negative determined by most recent local assessment\n* Willing and able to provide archival or newly obtained formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks\n* Participants must have received:\n\n  * Prior systemic therapy with platinum, fluorouracil, or taxane for locally advanced unresectable or metastatic disease\n  * Progression within 6 months of last dose of (neo)adjuvant cytotoxic chemotherapy is considered as 1 line of systemic therapy for LA/mGC/GEJC\n  * Prior anti-PD-(L)1 therapy is allowed\n  * No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADC) for LA/mGC/GEJC\n* Must not have received prior treatment with HER2 directed therapy\n\nCohort D (HER2+ LA/mGC/GEJC) Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma\n* Locally-advanced, unresectable, or metastatic stage\n* HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)\n* Participants must have:\n\n  * Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.\n  * Prior T-DXd treatment is allowed\n  * Prior PD1 inhibitor therapy is allowed\n  * No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mGC/GEJC\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hypersensitivity to any excipient contained in the drug formulation of disitamab vedotin or tucatinib\n* Prior therapy with ADCs with MMAE payload\n* Prior therapy with tucatinib\n* Active CNS and/or leptomeningeal metastasis.\n* Participants who have received prior systemic anticancer treatment including investigational agents within 4 weeks prior to first dose of study treatment\n* History of other invasive malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.\n* Unable to swallow oral tablets or capsules or any significant GI disease which would preclude the adequate oral absorption of medications",
    "miscellaneous_criteria": ""
}